Egylok (metoprolol) tablets 100 mg. №60 vial

Description

Egylok (metoprolol) Composition
active substance: metoprolol;

1 tablet contains 100 mg metoprolol tartrate;

Egylok (metoprolol) excipients: magnesium stearate, povidone, colloidal silicon dioxide, sodium starch (type A), microcrystalline cellulose.

Egylok (metoprolol) Dosage form
Pills.

Basic physical and chemical properties: 100 mg: white or almost white, round biconvex, with a chamfer, a line on one side and engraved with the stylized letter “E” and the number 432 on the other, without or almost odorless.

The tablets can be divided into equal portions.

Pharmacotherapeutic group
Selective blockers of β-adrenergic receptors. ATX code С07А В02.

Pharmacodynamics
Metoprolol is a cardioselective β1-adrenergic receptor blocker. It does not have a membrane stabilizing effect and does not have ICA.

It suppresses the cardiac effects of increased sympathetic activity, significantly reduces heart rate, cardiac contractility, cardiac output and blood pressure.

With arterial hypertension, metoprolol lowers blood pressure in patients both in the standing position and in the supine position. The long-term antihypertensive effect of the drug is associated with a gradual decrease in total peripheral vascular resistance.

In patients with arterial hypertension, prolonged use of the drug leads to a statistically significant decrease in left ventricular mass and an improvement in left ventricular diastolic function.

In men with mild to moderate arterial hypertension, metoprolol reduces mortality caused by cardiovascular diseases (primarily the incidence of sudden deaths, fatal myocardial infarctions and strokes).

By lowering systemic blood pressure, reducing heart rate and heart contractility, metoprolol reduces myocardial oxygen demand. By decreasing the heart rate and thus lengthening the duration of diastole, metoprolol improves perfusion and oxygenation of areas of the myocardium with impaired blood supply.

In addition, the drug reduces the incidence, duration and severity of angina attacks, as well as asymptomatic ischemia, and increases exercise tolerance.

Indications
Arterial hypertension.

Angina pectoris (including post-infarction).

Arrhythmia (including supraventricular tachycardia).

Prevention of cardiac death and re-infarction after the acute phase of myocardial infarction.

As part of complex therapy for thyrotoxicosis.

Prevention of migraine attacks.

Contraindications
hypersensitivity to drug components or other β-blockers;
blockade (AV block) of II and III degrees, sinoatrial block;
sick sinus syndrome;
decompensated heart failure (pulmonary edema, hypoperfusion syndrome or arterial hypotension) long-term or intermittent isotropic therapy with β-receptor agonists;
severe bradycardia (heart rate (HR) ≤ 45 in 1 min);
cardiogenic shock;
severe peripheral circulatory disorders with pain or trophic changes;
arterial hypotension (systolic blood pressure <100 mm Hg);
metabolic acidosis;
untreated pherochromocytoma;
long-term or intermittent inotropic therapy with β-receptor agonists;
concomitant therapy with MAO-A inhibitors;
severe bronchial asthma, a severe form of chronic obstructive bronchopulmonary diseases;
the use of metoprolol is contraindicated in patients undergoing intravenous administration of calcium antagonists such as verapamil and diltiazem or other antiarrhythmic drugs (disopyramide).
Metoprolol should not be administered to patients with suspected acute myocardial infarction with a heart rate of less than 45 beats / min, a P-Q interval> 0.24 s, or a systolic blood pressure <100 mm Hg.

Note. Patients with decompensated heart failure are well tolerated by other drugs, the use of metoprolol is possible with an individual dose selection.